In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of udpglucuronosyltransferases 1a1 and 1a9

Drug Metabolism and Disposition

Volumn 29, Issue 4 I, 2001, Pages 407-414

  Hagenauer, Birgit ^a   Salamon, Alexandra ^a   Thalhammer, Therese ^a   Kunert, Olaf ^b   Haslinger, Ernst ^b   Klingler, Paul ^c   Senderowicz, Adrian M ^d   Sausville, Edward A ^e   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 O BETA GLUCOPYRANURONOSYLFLAVOPIRIDOL; 5' DIPHOSPHOGLUCURONIC ACID; 7 O BETA GLUCOPYRANURONOSYLFLAVOPIRIDOL; ANTINEOPLASTIC AGENT; BILIRUBIN; FLAVOPIRIDOL; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; ULTRAVIOLET RADIATION;

ANIMALS; CYCLIN-DEPENDENT KINASES; DETERGENTS; ENZYME INHIBITORS; FLAVONOIDS; GLUCURONIC ACIDS; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES, LIVER; PIPERIDINES; RATS; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0035064435     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Flavopiridol induces apoptosis of normal lyphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
2. Flavopiridol: A cytotoxic flavone that induces cell death in noncyclic A549 human lung carcinoma cells
3. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
4. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
5. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
6. Steroidal saponins from Asperagus africanus
7. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
8. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein
9. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins
10. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
11. Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: Implication for cyclosporine metabolism
12. Modulation of liver canicular transport processes by the tyrosine kinase inhibitor genistein: Implication of genistein metabolites in rats
13. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
14. Growth inhibition with reversible cell arrest of carcinoma cells by flavone L86-8275
15. Potent inhibition of CDC2 kinase by the flavonoid L86-8275
16. Protein measurement with the Folin phenol reagent
17. Flavopiridol pharmacokinetics suggest enterohepatic circulation
18. Ultraviolet-visible absorption spectroscopy
19. Drug glucuronidation by human renal UDP-glucuronosyltransferases
20. 1/S cell cycle blockers and inhibitors of cyclin dependent kinases suppress camptothecin-induced neuronal apoptosis
21. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
22. Flavopiridol, a novel cyclin-dependent kinase inhibitor suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
23. Structural and functional studies of UDP-glucuronosyltransferases
24. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
25. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
26. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
27. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
28. Phase I trial of continuous infusion of flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
29. Preclinical and clinical development of cyclin-dependent kinase modulators
30. Phase I clinical and pharmacokinetic trial of flavopiridol
31. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells